FTSE MIB
34.709,73 +52,38 (+0,15%) Dow Jones
39.634,84 +122,00 (+0,31%) Nasdaq
16.350,26 +9,39 (+0,06%) Nikkei 225
38.179,46 -49,65 (-0,13%) Petrolio
79,06 +0,80 (+1,02%) Bitcoin EUR
58.078,60 +1.485,06 (+2,62%)
Cocrystal Pharma, Inc. (COCP)
| Chiusura precedente | 1,7200 |
| Aperto | 1,8100 |
| Denaro | 0,0000 x 0 |
| Lettera | 1,8000 x 100 |
| Min-Max giorno | 1,7984 - 1,8100 |
| Intervallo di 52 settimane | 1,3300 - 3,2900 |
| Volume | |
| Media Volume | 16.124 |
| Capitalizzazione | 18,297M |
| Beta (5 anni mensile) | 1,29 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,8700 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,67 |
GlobeNewswireCocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988. This pan-viral protease inhibitor was discovered using the Company’s proprietary structure-based drug discovery platform technology. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of or
- GlobeNewswire
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel small molecule antiviral therapeutics, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Cocrystal presentation will be available on the IR Calendar section of the Company’s website beginning Monday
- GlobeNewswire
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
On track to begin a Phase 2a trial in the second half of 2023 with CC-42344 for the treatment of pandemic and seasonal influenza ASelected the novel protease inhibitor CDI-988 as development lead in the oral norovirus programCDI-988, the first potential dual coronavirus-norovirus oral antiviral, was cleared by the Australian regulatory agency for evaluation in healthy volunteers BOTHELL, Wash., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) rep
